Drug intelligence / Profile preview

hs-10365

Development stage: Phase 2
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HS-10365 is an orally bioavailable, highly potent, and selective small molecule inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET). Developed by Jiangsu Hansoh Pharmaceutical Group, it selectively binds to and inhibits RET activity, blocking downstream signaling pathways involved in tumor cell proliferation and survival. HS-10365 has demonstrated promising antitumor activity in patients with RET gene fusion-positive non-small cell lung cancer (NSCLC) and other advanced solid tumors harboring RET alterations. Clinical trials have shown a manageable safety profile and favorable pharmacokinetic properties. The drug is being evaluated in Phase 1/2 clinical studies for advanced or metastatic malignant solid tumors, including NSCLC, medullary thyroid carcinoma (MTC), radioiodine-refractory thyroid cancer, neuroblastoma, and other cancers with RET gene abnormalities.

Other names: RET inhibitor HS-10365

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on hs-10365.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hs-10365.

Explore the full profile